Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Prepaid Assets (2023 - 2026)

ArriVent BioPharma has reported Prepaid Assets over the past 4 years, most recently at $952000.0 for Q1 2026.

  • Quarterly results put Prepaid Assets at $952000.0 for Q1 2026, down 88.07% from a year ago — trailing twelve months through Mar 2026 was $952000.0 (down 88.07% YoY), and the annual figure for FY2025 was $60000.0, down 65.52%.
  • Prepaid Assets reached $952000.0 in Q1 2026 per AVBP's latest filing, up from $60000.0 in the prior quarter.
  • Across five years, Prepaid Assets topped out at $14.5 million in Q2 2025 and bottomed at $60000.0 in Q4 2025.
  • Median Prepaid Assets over the past 4 years was $4.4 million (2024), compared with a mean of $5.0 million.
  • The largest annual shift saw Prepaid Assets plummeted 98.18% in 2024 before it skyrocketed 1841.21% in 2025.
  • Over 4 years, Prepaid Assets stood at $9.6 million in 2023, then tumbled by 98.18% to $174000.0 in 2024, then plummeted by 65.52% to $60000.0 in 2025, then skyrocketed by 1486.67% to $952000.0 in 2026.
  • Business Quant data shows Prepaid Assets for AVBP at $952000.0 in Q1 2026, $60000.0 in Q4 2025, and $450000.0 in Q3 2025.